| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.AMJMED.2004.04.031 |
| P698 | PubMed publication ID | 15639201 |
| P50 | author | John Ioannidis | Q6251482 |
| Frank van den Hoogen | Q47265626 | ||
| Athanasios Georgountzos | Q59558296 | ||
| Haralampos Moutsopoulos | Q87896552 | ||
| Panayiotis G Vlachoyiannopoulos | Q96683096 | ||
| Marco Matucci-Cerinic | Q19859583 | ||
| P2093 | author name string | Jacob M van Laar | |
| Anna-Bettina Haidich | |||
| Hidekata Yasuoka | |||
| Masataka Kuwana | |||
| Thomas A Medsger | |||
| Clement J Michet | |||
| Frank van den Hoogen | |||
| Mary Lucas | |||
| Liane Te Boome | |||
| Nicolette L Verbeet | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 2-10 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Mortality in systemic sclerosis: an international meta-analysis of individual patient data | |
| P478 | volume | 118 |
| Q37683545 | A Marked Response to Immunosuppressive Intervention for Abruptly Occurring Cardiac Complications in a Case of Juvenile Systemic Sclerosis Overlapped with Dermatomyositis |
| Q61974481 | A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma |
| Q26829931 | A meta-analysis of mortality in rheumatic diseases |
| Q38148952 | Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature. |
| Q93050475 | Abnormalities of heart rate turbulence and heart rate variability as indicators of increased cardiovascular risk in patients with systemic sclerosis |
| Q35628723 | Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. |
| Q48361487 | Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. |
| Q80059890 | Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations |
| Q58553753 | Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis |
| Q42610157 | Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial |
| Q37311078 | Autologous stem cell transplantation for systemic sclerosis |
| Q51166044 | Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. |
| Q26776432 | Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? |
| Q56978245 | Bosentan for the treatment of scleroderma |
| Q59192506 | Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans |
| Q44584276 | Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan |
| Q33160288 | Cardiac involvement in systemic sclerosis |
| Q41189863 | Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival |
| Q39036353 | Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. |
| Q54311619 | Cardiomyopathy in murine models of systemic sclerosis. |
| Q39322066 | Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners |
| Q30355778 | Cardiovascular magnetic resonance imaging: clinical implications in the evaluation of connective tissue diseases. |
| Q35954516 | Changes in causes of death in systemic sclerosis, 1972-2002 |
| Q36289875 | Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis |
| Q35108749 | Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling |
| Q39245866 | Chronic pruritus in autoimmune dermatoses : results of a comparative survey |
| Q38825869 | Clinical Trial Design Issues in Systemic Sclerosis: an Update |
| Q33903786 | Clinical and genetic factors predictive of mortality in early systemic sclerosis |
| Q35597574 | Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy |
| Q49486890 | Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database |
| Q35953368 | Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database |
| Q39105586 | Cognitive-behavioural therapy targeting fear of progression in an interdisciplinary care program: a case study in systemic sclerosis |
| Q38175430 | Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety |
| Q41135602 | Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis |
| Q34267840 | Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. |
| Q47633128 | Determinants of mortality in systemic sclerosis: a focused review |
| Q35156880 | Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort |
| Q38601342 | Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease |
| Q33832379 | Diagnosis and management of pulmonary hypertension in systemic sclerosis |
| Q61913936 | Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis |
| Q34485231 | Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis |
| Q26864740 | Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis |
| Q36757042 | Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors |
| Q38937968 | Early morphologic and functional changes of atherosclerosis in systemic sclerosis-a systematic review and meta-analysis |
| Q36193496 | Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients |
| Q92675244 | Electrocardiographic markers for the prediction of ventricular arrhythmias in patients with systemic sclerosis |
| Q51160191 | Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. |
| Q57214016 | Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study |
| Q48348597 | Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level |
| Q36871425 | Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma |
| Q34545752 | Genetics of scleroderma: implications for personalized medicine? |
| Q53365480 | HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. |
| Q36020897 | Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation |
| Q87919676 | Heart involvement in systemic sclerosis: a combined echocardiographic and scintigraphic study |
| Q34032884 | Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. |
| Q36067732 | Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome? |
| Q45007419 | Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis |
| Q38161937 | Innate immunity in systemic sclerosis pathogenesis |
| Q50097908 | Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. |
| Q30432895 | Left atrial dysfunction detected by speckle tracking in patients with systemic sclerosis |
| Q46306260 | Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a |
| Q34585544 | Lidocaine for systemic sclerosis: a double-blind randomized clinical trial |
| Q51494850 | Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. |
| Q38733776 | Lung Transplantation in Patients With Systemic Sclerosis |
| Q40502385 | Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. |
| Q34627273 | Meta-analysis in medical research. |
| Q34653727 | Mortality in systemic sclerosis-a single centre study from the UK. |
| Q40173071 | Mortality in the Waikato Hospital Systemic Sclerosis Cohort. |
| Q39322803 | Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells |
| Q36765781 | New therapeutic strategies in the management of systemic sclerosis |
| Q53187497 | Oesophageal dilatation on high-resolution CT chest in systemic sclerosis: what does it signify? |
| Q34700520 | On the respiratory mechanics measured by forced oscillation technique in patients with systemic sclerosis. |
| Q53376044 | Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis. |
| Q47835792 | Points to consider when doing a trial primarily involving the heart |
| Q37970887 | Predictors of early mortality in systemic sclerosis: a case-control study comparing early versus late mortality in systemic sclerosis |
| Q34346178 | Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort |
| Q51226359 | Premature atherosclerosis in systemic sclerosis patients: Its relation to disease parameters and to traditional risk factors. |
| Q36596341 | Primary myocardial involvement in systemic sclerosis |
| Q30453741 | Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests |
| Q37778578 | Pulmonary Manifestations of Scleroderma and Mixed Connective Tissue Disease |
| Q43754038 | Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography |
| Q51503621 | Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. |
| Q83106907 | Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables |
| Q37176160 | Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death |
| Q35851777 | Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis |
| Q57153464 | Replacement myocardial fibrosis at the site of late gadolinium enhancement on magnetic resonance imaging in a patient with diffuse cutaneous systemic sclerosis: An autopsy report |
| Q35036736 | Right bundle branch block: a predictor of mortality in early systemic sclerosis |
| Q84475445 | Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma |
| Q46578323 | Right-heart failure after right heart catheterization in a patient with scleroderma and suspected pulmonary hypertension |
| Q42698900 | Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). |
| Q37754590 | Scleroderma lung disease: treatment with cyclophosphamide |
| Q36815081 | Scleroderma lung: pathogenesis, evaluation and current therapy |
| Q41973328 | Significance of various pulmonary and extrapulmonary abnormalities on HRCT of the chest in scleroderma lung |
| Q38287103 | Stem cell autograft and allograft in autoimmune diseases |
| Q38701990 | Strategy for treatment of fibrosis in systemic sclerosis: Present and future |
| Q64092008 | Subclinical biventricular systolic dysfunction in patients with systemic sclerosis |
| Q40809160 | Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran |
| Q64078682 | Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature |
| Q27687340 | Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. |
| Q38103626 | Systemic sclerosis and the gut. |
| Q34295337 | Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings |
| Q37143961 | T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q89099219 | The Assessment of Tp-e Interval and Tp-e/QT Ratio in Patients With Systemic Sclerosis |
| Q36555885 | The Extrapulmonary Manifestations of Systemic Sclerosis on Chest High Resolution Computed Tomography |
| Q36645934 | The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. |
| Q41673061 | The economic burden and health-related quality of life associated with systemic sclerosis in France |
| Q37973712 | The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies |
| Q89366404 | The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink |
| Q47550064 | The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. |
| Q38490653 | The prognostic factors of systemic sclerosis for survival among Koreans. |
| Q36773107 | The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. |
| Q35517421 | The right ventricle in scleroderma (2013 Grover Conference Series). |
| Q38162278 | To spare or not to spare…? The aortic valve in scleroderma and aortic root aneurysm |
| Q26864958 | Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies |
| Q84583792 | What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG) |
| Q79423269 | [Therapeutic management of systemic sclerosis] |
| Q81235668 | [Therapy of systemic sclerosis] |
| Q79788905 | [Treatment of systemic scleroderma: update] |
| Q79836579 | [Treatment of systemic sclerosis] |
| Q37064457 | miR-155 in the progression of lung fibrosis in systemic sclerosis. |
Search more.